<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="case-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Pathol. Oncol. Res.</journal-id>
<journal-title>Pathology &#x26; Oncology Research</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Pathol. Oncol. Res.</abbrev-journal-title>
<issn pub-type="epub">1532-2807</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1612076</article-id>
<article-id pub-id-type="doi">10.3389/pore.2025.1612076</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pathology and Oncology Archive</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Case Report: Osteoclastic giant cell-rich cervical squamous cell carcinoma&#x2014;the first reported case of a clinically silent early-detected keratinizing subtype with a detailed literature comparison</article-title>
<alt-title alt-title-type="left-running-head">Fulawka et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/pore.2025.1612076">10.3389/pore.2025.1612076</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fulawka</surname>
<given-names>Lukasz</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2939857/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dawiec</surname>
<given-names>Beata</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2980930/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Homola</surname>
<given-names>Wojciech</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Halon</surname>
<given-names>Agnieszka</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Clinical and Experimental Pathology</institution>, <institution>Wroclaw Medical University</institution>, <addr-line>Wroclaw</addr-line>, <country>Poland</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Molecular Pathology Centre Cellgen</institution>, <addr-line>Wroclaw</addr-line>, <country>Poland</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Gynaecology and Obstetrics Centre FemiMea</institution>, <addr-line>Bielany Wroclawskie</addr-line>, <country>Poland</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/989597/overview">Stefano Restaino</ext-link>, Ospedale Santa Maria della Misericordia di Udine, Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Lukasz Fulawka, <email>lukasz.fulawka@umw.edu.pl</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>05</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>31</volume>
<elocation-id>1612076</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>01</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>05</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Fulawka, Dawiec, Homola and Halon.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Fulawka, Dawiec, Homola and Halon</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>We report the first case of an asymptomatic woman with osteoclast-like giant cell-rich cervical squamous cell carcinoma (OGC-rich cervical SCC), where the detection of cancer was made possible only by routine cytological screening. The presence of OGCs in cervical SCCs is an extremely rare phenomenon, with only 8 cases reported to date.</p>
</sec>
<sec>
<title>Case description</title>
<p>Two consecutive liquid-based cytology revealed high-grade squamous intraepithelial lesion (HSIL). Molecular testing detected HPV 18. Colposcopic findings strongly supported the clinical diagnosis of HSIL/suspicious for invasion. Histopathological examination of biopsy samples revealed typical keratinizing-type cervical SCC morphology. The patient subsequently underwent LEEP (loop electrosurgical excision procedure). Microscopic examination of resection specimen confirmed the previous diagnosis. Moreover, groups of large multinucleated cells were observed at the periphery of some invasive nests. Most of them presented the morphology of osteoclasts, whereas some giant cells were similar to Langhans cells. All the giant cells were positive for vimentin and CD68, negative for pancytokeratin. Owing to positive margins following the LEEP procedure, the patient underwent hysterectomy via the Wertheim technique. No adjuvant treatment was applied, and after the 9-month follow-up, the patient was alive with no recurrence.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Detailed literature review revealed that our case is the first case of keratinizing-subtype cervical OGC-rich SCC. Moreover, it is the youngest (33 yo.) patient with a significantly smaller diameter than previously reported cases. Unfortunately, owing to the small number of reported cases, the analysis did not allow us to draw conclusions about the potential prognostic or predictive value of OGC-rich morphology.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cervical cancer</kwd>
<kwd>HPV</kwd>
<kwd>cervical squamous cell carcinoma</kwd>
<kwd>osteoclast-like giant cells</kwd>
<kwd>osteoclastic giant cell-rich squamous cell carcinoma</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Cervical carcinoma is the most common malignancy of the female genital tract and the fourth most common type of cancer in women, with an incidence of 14.1/100 thousand females. It is also the third leading cause of death due to cancer in women, with a mortality rate of 7.1/100 thousand females [<xref ref-type="bibr" rid="B1">1</xref>].</p>
<p>Histologically, 80%&#x2013;90% of cervical cancers are squamous cell carcinomas (SCCs) [<xref ref-type="bibr" rid="B2">2</xref>]. The majority of cervical SCC cases (&#x3e;90&#x2013;95%) are HPV-associated [<xref ref-type="bibr" rid="B2">2</xref>]. HPV status is crucial from a clinical perspective because it is associated with a better prognosis and thus helps to prevent more aggressive therapy in patients who do not need it. For this reason, HPV status has been incorporated into the histological World Health Organization (WHO) classification of cervical SCC and adenocarcinoma [<xref ref-type="bibr" rid="B2">2</xref>]. HPV-associated neoplastic transformation is a well-known process leading to invasive SCC via precancerous lesions, namely, low-grade squamous intraepithelial lesion (LSIL), followed by high-grade squamous intraepithelial lesion (HSIL). It is widely accepted that 14 types of HPV have carcinogenic potential and are so-called high-risk HPV (HR HPV) types. Among HR HPV-associated lesions, HPV 16- and HPV 18-positive lesions carry the greatest risk of progression to malignancy [<xref ref-type="bibr" rid="B2">2</xref>].</p>
<p>Several histologic variants of cervical SCC have been described: nonkeratinizing, keratinizing, basaloid, papillary, warty/condylomatous, verrucous, squamotransitional, lymphoepithelial-like and spindled/sarcomatoid [<xref ref-type="bibr" rid="B2">2</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>]. A wide variety of grading systems for cervical SCC have been used, but none of them have been universally accepted or widely adopted in clinical practice [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>].</p>
<p>The Pap smear screening strategy for cervical cancer has been widely used for several decades. In Poland, it remained the sole primary test in state-funded population screening programs until early 2025. Currently, the primary test in population-based screening is transitioning to HPV detection by PCR, with a transitional period during which both methods are used concurrently. The screening targets women aged 25&#x2013;64, with Pap smears performed every 3&#xa0;years and HPV testing every 5&#xa0;years. Simultaneously, opportunistic screening &#x2014; using both methods at shorter intervals &#x2014; remains widespread in Poland. The presence of osteoclast-like giant cells (OGCs) has been reported in cancers at various anatomical locations, e.g., the skin, breast and pancreas [<xref ref-type="bibr" rid="B8">8</xref>]. Squamous cell carcinoma with OGCs is recognized as a histologic type of cutaneous SCC by the World Health Organization [<xref ref-type="bibr" rid="B9">9</xref>]. In the current WHO pancreatic tumor classification, undifferentiated carcinoma with osteoclast-like giant cells is one of the special histologic types of ductal adenocarcinoma [<xref ref-type="bibr" rid="B10">10</xref>]. Breast carcinoma with OGCs is considered a special morphologic pattern according to the 2019 WHO breast tumor classification and is most often reported in invasive carcinomas of no special type (ICs NST) [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>].</p>
<p>To the best of our knowledge, only eight cases of SCCs with OGCs of the uterine cervix have been reported to date (7 cases in full-text publications and 1 in a conference abstract) [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>]. Owing to its rarity, this type has not been recognized as a stand-alone histologic subtype or, at least, a special morphologic pattern recognized by the WHO [<xref ref-type="bibr" rid="B2">2</xref>]. This morphological phenomenon has not been mentioned in some generally respected books on gynecological pathology [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. However, in Blaustein&#x2019;s Pathology of the Female Genital Tract it is mentioned that &#x201c;ocasionally a foreign body giant cell reaction is observed&#x201d; at the periphery of tumor nests in G1 tumors [<xref ref-type="bibr" rid="B19">19</xref>]. The <ext-link ext-link-type="uri" xlink:href="http://Pathologyoutlines.com">Pathologyoutlines.com</ext-link> web service mentions OGCs as occasional phenomena in spindled/sarcomatoid variants of cervical SCC [<xref ref-type="bibr" rid="B3">3</xref>].</p>
</sec>
<sec id="s2">
<title>Case description</title>
<p>We report a case of a 33-year-old white woman with a medical history of one pregnancy and cesarean section. No comorbidities were reported in the patient&#x2019;s medical history and her family history was negative for cancer. The patient was asymptomatic at the time of the visit (May 2024). The patient reported that she was vaccinated with a quadrivalent vaccine, Gardasil (against HPV types 6, 11, 16, and 18), a few years ago. The medical record indicates that the results of the previous annual cervical cytology screening were reported as NILM (negative for intraepithelial lesion or malignancy). The only exception was an HPV 56 infection detected in 2011, which was followed by colposcopy and histopathologic examination, revealing chronic inflammation.</p>
<p>The patient came to the clinic for colposcopic evaluation due to HSIL (high-grade squamous intraepithelial lesion) results in two consecutive liquid-based cytology (LBC) in March and April 2024. Both LBC examinations were conducted with BD SurePath (Becton Dickinson, United States) via the automatic preparation system BD Totalys SlidePrep (Becton Dickinson, United States). The second LBC was used as a co-test, followed by the detection of 14 high-risk HPV types and genotyping via qPCR molecular testing with an Anyplex II HPV HR Detection kit (Seegene, South Korea), which was conducted using CFX96 Dx System (Bio-Rad, United States). Data analysis was performed using Seegene Viewer software (Seegene, South Korea). Nucleic acid isolation was performed with an Invisorb Spin Universal Kit (Invitek Molecular, Germany) according to the manufacturer&#x2019;s procedure. The type of HPV 18 was detected.</p>
<p>Colposcopy with biopsy for histopathological examination was conducted using Eva Pro digital colposcope. This examination revealed major abnormal colposcopic findings: rapid appearance of dense acetowhite epithelium, abnormal vessels, ridge sign and coarse punctation. The lesion was present on the upper and lower lips of the cervix and had an irregular surface with fragile vessels, highly supporting the clinical diagnosis of HSIL/suspicious for invasion (<xref ref-type="fig" rid="F1">Figure 1A</xref>). After acid solution treatment, a rapid appearance of dense acetowhite epithelium was observed, mostly on the lower lip, and also at 11 and 3 o&#x2019;clock (<xref ref-type="fig" rid="F1">Figures 1B&#x2013;D</xref>). The inner border sign was present on the lower lip. The ridge sign at 8 o&#x2019;clock, coarse punctation at the upper and right lower quadrants of the cervix and an irregular surface were the major abnormal colposcopic findings. Slight pinpoint bleeding that may indicate the presence of fragile vessels was visible. Targeted biopsy was taken from 3, 5, 8, 10, and 11 o&#x2019;clock. Endocervical curettage was performed.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Colposcopic appearance of the lesion. <bold>(A)</bold> Before acid solution treatment. Extensive lesion on upper and lower lip of the cervix with abnormal vessels. <bold>(B&#x2013;D)</bold> After acid solution treatment (B. 30&#xa0;s, C. 1&#xa0;min, D. 3&#xa0;min). Dense acetowhite epithelium, mostly on lower lip, and also at 11 and 3 o&#x2019;clock. The ridge sign at 8 o&#x2019;clock, coarse punctation at upper and right lower quadrant and an irregular surface. Slight pinpoint bleeding that may indicate presence of fragile vessels.</p>
</caption>
<graphic xlink:href="pore-31-1612076-g001.tif"/>
</fig>
<p>Histopathological examination revealed the full thickness of highly atypical squamous epithelial cells, with deep involvement of the endocervical glands, making the diagnosis of high-grade squamous intraepithelial lesion/carcinoma <italic>in situ</italic> (HSIL/CIS). However, the biopsy was too shallow, and the specimen was too fragmented to be examined for possible tumor invasion.</p>
<p>One month after colposcopy, the patient underwent LEEP/LLETZ (loop electrosurgical excision procedure/large loop excision of the transformation zone), followed by histopathological examination. The patient was informed that, owing to the extent of the transformation zone, there is a risk of nonradical resection of the lesion. The procedure was performed under local anaesthesia. Each specimen was taken from the upper and lower lips separately. There were no complications. On gross examination, two oriented fragments of the upper and lower lips were detected, measuring 2.6 &#xd7; 1.6 &#xd7; 0.8&#xa0;cm and 2.5 &#xd7; 1.4 &#xd7; 0.8&#xa0;cm, respectively. Barely visible slight discolouration of the mucosa surrounding the external os area on the lower lip was observed. The specimens were painted, and multiple sections were submitted according to the grossing procedure.</p>
<p>On microscopic examination, the invasive tumor component was easily recognizable and surrounded by HSIL at the edges. The depth of invasion was 4.5&#xa0;mm, &#x201c;measured from the deepest focus of tumor invasion to the base of the nearest dysplastic crypt,&#x201d; according to recommendations [<xref ref-type="bibr" rid="B6">6</xref>]. The highest horizontal dimension of the invasive component was 10.5&#xa0;mm. Nests of large cells with abundant eosinophilic cytoplasm, atypical nuclei, distinct intercellular borders, and maturation towards the edges of the nests were visible (<xref ref-type="fig" rid="F2">Figures 2A,B</xref>). Keratin pearls, some of which were large, were observed throughout the tumor. Moreover, areas of highly atypical cells with poor cytoplasm and crowded nuclei were detected, some of which were pleomorphic with a few large bizarre nuclei (<xref ref-type="fig" rid="F2">Figure 2F</xref>). Mitotically active regions were present, including atypical mitoses (<xref ref-type="fig" rid="F2">Figure 2F</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Morphological features of invasive component. <bold>(A)</bold> Nests of large cells with abundant slightly eosinophilic cytoplasm, maturating towards the edges of the nests, surrounded by lymphocytic infiltration. Keratin pearls (asterisk) surrounded by giant cells with peripherally located nuclei, resembling Langhans giant cells. <bold>(B)</bold> Mature cells at the periphery of the nest with distinct intercellular borders. The group of multinucleated giant cells of both osteoclast-like and Langhans-like morphology. <bold>(C)</bold> The group of osteoclast-like giant cells at the periphery of the nest. The stroma infiltrated with lymphocytes. <bold>(D)</bold> Higher magnification of keratin pearl surrounded by Langhans-like and osteoclast-like giant cells. <bold>(E)</bold> Large multinucleated cell with necrotic area and cellular debris in the middle (arrow) (probably the area outside the cell surrounded by its cytoplasm). <bold>(F)</bold> The area of highly atypical cells, some of them pleomorphic with a few large bizarre nuclei (asterisk) and atypical mitoses (arrow).</p>
</caption>
<graphic xlink:href="pore-31-1612076-g002.tif"/>
</fig>
<p>On a closer look, groups of large multinucleated cells were observed at the periphery of some nests. They contained slightly eosinophilic cytoplasm and from a few to a few dozen nuclei. Most of them had nuclei scattered throughout the cytoplasm, making them similar to osteoclasts or foreign body giant cells (<xref ref-type="fig" rid="F2">Figures 2B&#x2013;D</xref>). Moreover, in some giant cells, the nuclei were located peripherally and arranged in a horseshoe-shaped pattern resembling Langhans giant cells (<xref ref-type="fig" rid="F1">Figures 2A,B,D</xref>). Giant cells were located at the edges of the tumor nests or formed aggregates. Some groups of both types of multinucleated giant cells surrounded large keratin pearls (<xref ref-type="fig" rid="F1">Figures 2A,D</xref>). The lymphocytic infiltration in the stroma surrounding the tumor nests was clearly visible, with only scattered intratumoral lymphocytes. Vascular and perineural invasion were not detected. However, a second-look examination revealed one area suspicious for lymphovascular invasion (necrotic tissue within an endothelium-lined space).</p>
<p>Immunohistochemistry was performed automatically on a Benchmark Ultra (Roche Diagnostics, Switzerland) with the following antibodies: pancytokeratin (clone AE1/AE3/PCK26, Roche Diagnostics, Switzerland), vimentin (clone V9, Roche Diagnostics, Switzerland) and CD68 (clone KP-1, Roche Diagnostics, Switzerland). The tumor cells were positive for pancytokeratin, negative for vimentin and CD68 (<xref ref-type="fig" rid="F3">Figures 3 A&#x2013;C</xref>). Whereas OGCs were positive for vimentin and CD68, negative for pancytokeratin. A final diagnosis of osteoclastic giant cell-rich squamous cell carcinoma, HPV-associated, G2, pT1a2 NX MX with positive surgical margins was made. Given that a universally accepted grading system of cervical SCC does not exist, the grade assessment of this tumor is described in the Discussion section.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Immunohistochemical characterization of the lesion. <bold>(A)</bold> Pancytokeratin: positive in tumor cells, negative in multinucleated cells (asterisk). <bold>(B)</bold> Vimentin: negative in tumor cells (asterisk), positive in multinucleated cells. <bold>(C)</bold> CD68-positive osteoclast-like giant cells.</p>
</caption>
<graphic xlink:href="pore-31-1612076-g003.tif"/>
</fig>
<p>Owing to positive margins following the LEEP procedure and the patient&#x2019;s oncological anxiety, the patient was admitted to the gynaecological ward one and a half months later (July 2024) to undergo a more radical excision. Preoperative TV USG (transvaginal ultrasound) revealed a hypoechogenic lesion on the left side of the cervix, with dimensions of 21 &#xd7; 12 &#xd7; 25&#xa0;mm, involving the cervical canal but not reaching the uterine body. The lesion demonstrated low vascularity. The parametrium was free of lesions, and the iliac vessel area showed no enlarged lymph nodes. The patient was deemed eligible for planned surgery, including microstaging of the lymph nodes. In the first stage of surgery, an intraoperative biopsy of the sentinel lymph nodes was performed via laparoscopy. Indocyanine green (ICG) was injected into the cervix at the 3 and 9 o&#x2019;clock positions to facilitate lymphatic mapping. Histopathological examination of intraoperative frozen sections revealed no cancer cells. In the subsequent stage, a radical hysterectomy using the Wertheim technique was performed, including total resection of the uterus with the parametrium, bilateral uterosacral ligaments, and pelvic lymphadenectomy via laparotomy. The patient had no symptoms after the procedure. Routine laboratory tests revealed no abnormalities. The postoperative histopathological diagnosis was squamous cell carcinoma, HPV-associated, G2, pT1a1 N0 MX. The depth of invasion was 2.8&#xa0;mm, and the highest horizontal dimension of the invasive component was 3.2&#xa0;mm. Lymphovascular and perineural invasion were not detected. In total, 21 pelvic lymph nodes were resected, none of which contained tumor metastases. A focus of endometriosis was found in the right parametrium. After a full histopathological report, it was decided that adjuvant treatment was not necessary.</p>
</sec>
<sec id="s3">
<title>Discussion and conclusion</title>
<p>To date, 8 cases of OGC-rich squamous cell carcinoma of the uterine cervix have been reported (7 cases in full-text publications and 1 in a conference abstract) [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>]. All the authors of these previous papers are consistent with the view of the immune cell-derived nature of OGCs. All of them reported that OGCs were negative for epidermal markers, most notably pancytokeratin, and positive for mesenchymal (vimentin) and monocyte lineage (CD68) markers. The nonneoplastic nature of OGCs was also confirmed by the nonatypical morphology of cell nuclei in all of the reports [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>].</p>
<p>The etiopathology of OGC-rich SCC of the uterine cervix is another interesting factor. Only 3 cases, incl. present, have had HPV etiology confirmed (<xref ref-type="table" rid="T1">Table 1</xref>). However, in more than half of the cases (5/9 cases), the HPV status has not been reported. Therefore, 75% of reported cases of known HPV status (3/4 cases) were HPV-positive. In general, more than 90% of SCCs of the uterine cervix are HPV-associated [<xref ref-type="bibr" rid="B2">2</xref>]. Interestingly, two different types of HR HPV were detected in the medical history of the present case. The molecular testing for HR HPV conducted in 2024 as a co-test detected HPV 18. However, according to medical interview, HPV 56 infection was detected in 2011. There are two solutions to this phenomenon.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The clinico-pathologic characteristics of reported cases of OGCs-rich cervical SCC.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Case no.</th>
<th align="center">First author, year</th>
<th align="center">Country</th>
<th align="center">Age (years)</th>
<th align="center">Tumor diameter (mm)</th>
<th align="center">Growth pattern</th>
<th align="center">Stage (FIGO)</th>
<th align="center">HPV PCR</th>
<th align="center">Histological type</th>
<th align="center">Treatment</th>
<th align="center">Status</th>
<th align="center">Follow- up period</th>
<th align="center">IHC staining of OGCs</th>
<th align="center">Ref.</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="left">Pang, 1998</td>
<td align="left">Taiwan</td>
<td align="center">65</td>
<td align="center">60</td>
<td align="left">Exophytic</td>
<td align="center">IB2</td>
<td align="center">Not reported</td>
<td align="left">Sarcomatoid</td>
<td align="left">SP, RT and CT</td>
<td align="center">DOD</td>
<td align="left">7 weeks</td>
<td align="left">CD68</td>
<td align="center">[<xref ref-type="bibr" rid="B15">15</xref>]</td>
</tr>
<tr>
<td align="center">2</td>
<td align="left">Pang, 1998</td>
<td align="left">Taiwan</td>
<td align="center">61</td>
<td align="center">50</td>
<td align="left">Exophytic</td>
<td align="center">IB2</td>
<td align="center">Not reported</td>
<td align="left">Sarcomatoid</td>
<td align="left">SP, RT and CT</td>
<td align="center">DOD</td>
<td align="left">14 months</td>
<td align="left">CD68</td>
<td align="center">[<xref ref-type="bibr" rid="B15">15</xref>]</td>
</tr>
<tr>
<td align="center">3</td>
<td align="left">Singh et al., 2012</td>
<td align="left">India</td>
<td align="center">60</td>
<td align="center">45</td>
<td align="left">Infiltrating</td>
<td align="center">IB2</td>
<td align="center">Negative</td>
<td align="left">Non-keratinizing</td>
<td align="left">RT and CT</td>
<td align="center">ACR</td>
<td align="left">6 months</td>
<td align="left">CD68</td>
<td align="center">[<xref ref-type="bibr" rid="B14">14</xref>]</td>
</tr>
<tr>
<td align="center">4</td>
<td align="left">Yu et al., 2014</td>
<td align="left">China</td>
<td align="center">84</td>
<td align="center">50</td>
<td align="left">Exophytic</td>
<td align="center">IB2</td>
<td align="center">Not reported</td>
<td align="left">Non-keratinizing</td>
<td align="left">RT</td>
<td align="center">DOD</td>
<td align="left">8 months</td>
<td align="left">CD68, vimentin</td>
<td align="center">[<xref ref-type="bibr" rid="B17">17</xref>]</td>
</tr>
<tr>
<td align="center">5</td>
<td align="left">Alem&#xe1;n-Meza et al., 2014</td>
<td align="left">Mexico</td>
<td align="center">49</td>
<td align="center">27</td>
<td align="left">Exophytic</td>
<td align="center">IB1</td>
<td align="center">Not reported</td>
<td align="left">Non-keratinizing</td>
<td align="left">SP</td>
<td align="center">ACR</td>
<td align="left">7 months</td>
<td align="left">CD68, vimentin</td>
<td align="center">[<xref ref-type="bibr" rid="B16">16</xref>]</td>
</tr>
<tr>
<td align="center">6</td>
<td align="left">Dejima et al., 2020</td>
<td align="left">Japan</td>
<td align="center">49</td>
<td align="center">25</td>
<td align="left">Infiltrating</td>
<td align="center">IB1</td>
<td align="center">16</td>
<td align="left">Non-keratinizing</td>
<td align="left">SP, RT and CT</td>
<td align="center">ACR</td>
<td align="left">22 months</td>
<td align="left">CD68, CD204</td>
<td align="center">[<xref ref-type="bibr" rid="B13">13</xref>]</td>
</tr>
<tr>
<td align="center">7</td>
<td align="left">Tziakou et al., 2020</td>
<td align="left">Greece</td>
<td align="center">79</td>
<td align="center">no data av<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</td>
<td align="left">Exophytic</td>
<td align="center">no data av<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</td>
<td align="center">no data av<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>
</td>
<td align="left">Non-keratinizing</td>
<td align="left">RT</td>
<td align="center">DOD</td>
<td align="left">8 months</td>
<td align="left">CD68, vimentin</td>
<td align="center">[<xref ref-type="bibr" rid="B18">18</xref>]</td>
</tr>
<tr>
<td align="center">8</td>
<td align="left">Castillo et al., 2024</td>
<td align="left">Spain</td>
<td align="center">38</td>
<td align="center">35</td>
<td align="left">Exophytic</td>
<td align="center">IB1</td>
<td align="center">34</td>
<td align="left">Non-keratinizing</td>
<td align="left">SP</td>
<td align="center">ACR</td>
<td align="left">24 months</td>
<td align="left">CD68, vimentin</td>
<td align="center">[<xref ref-type="bibr" rid="B8">8</xref>]</td>
</tr>
<tr>
<td align="center">9</td>
<td align="left">Present case, 2024</td>
<td align="left">Poland</td>
<td align="center">33</td>
<td align="center">10.5<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref>
</td>
<td align="left">Superficial</td>
<td align="center">IB1</td>
<td align="center">18 (56)<xref ref-type="table-fn" rid="Tfn3">
<sup>c</sup>
</xref>
</td>
<td align="left">Keratinizing</td>
<td align="left">no adj. Treatment</td>
<td align="center">ACR</td>
<td align="left">9 months<xref ref-type="table-fn" rid="Tfn4">
<sup>d</sup>
</xref>
</td>
<td align="left">CD68, vimentin</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>
<sup>a</sup>
</label>
<p>No data available - conference abstract.</p>
</fn>
<fn id="Tfn2">
<label>
<sup>b</sup>
</label>
<p>Microscopic measurement.</p>
</fn>
<fn id="Tfn3">
<label>
<sup>c</sup>
</label>
<p>HPV 18 was detected simultaneously with HSIL in co-test (HPV 56 was detected in the past according to medical interview) - see the Discussion section.</p>
</fn>
<fn id="Tfn4">
<label>
<sup>d</sup>
</label>
<p>since HSIL result in LBC; IHC, immunohistochemistry.</p>
</fn>
<fn>
<p>RT, radiotherapy; CT, chemotherapy; SP, surgical procedure; DOD, dead of disease; ACR, alive with complete regression.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>First, in our experience, discrepancies in HPV genotyping results between different test kits or laboratories&#x2014;even among reputable facilities using validated methods&#x2014;can be substantial (unpublished results from an interlaboratory comparison involving 350 women). Unfortunately, we lack detailed information about the 2011 test, including the qPCR kit used (assuming that qPCR was used, which was already predominant at that time), nucleic acid isolation kit, type of preservative solution and the credibility of laboratory conducting the test. Second, a biological explanation may be considered. The 13-year interval between the two tests raises the possibility of sequential infections. It is theoretically plausible that the patient first cleared the HPV 56 infection and later acquired a new HPV 18 infection. Only the latter may have led to viral genome integration and oncogenesis. However, it generally takes 15&#x2013;30&#xa0;years for persistent HR HPV infection to progress to invasive cervical carcinoma [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B20">20</xref>]. Of note, the woman in our case was vaccinated a few years before the detection of HSIL and cancer. As reported in the literature, vaccination does not eliminate established HPV infections or prevent progression of pre-existing HPV-related lesions, but it may reduce the risk of acquiring new infections [<xref ref-type="bibr" rid="B21">21</xref>]. To the best of our knowledge, the present case is the first reported OGC-rich cervical SCC of the keratinizing subtype. Two-thirds (6/9 patients) had nonkeratinizing morphology, and approximately 20% (2/9 patients) had sarcomatoid morphology (<xref ref-type="table" rid="T1">Table 1</xref>). This is not surprising because, in general, the nonkeratinizing pattern is the most frequently identified subtype of cervical SCC [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. The other authors observed multinucleated giant cells interspersed between tumor cells [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. In contrast, the giant cells in the present case were located peripherally to the tumor nests or formed aggregates. We did not detect individual giant cells scattered over the tumor area. None of the authors have described the peripherally located nuclei of multinucleated cells, resembling Langhans giant cells. However, detailed analysis of the images presented in these papers revealed cells of this morphology, incl. The horseshoe-shaped pattern, resembling Langhans giant cells, which for some unknown reason, was not reported by any of the authors [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Lymphocytic infiltration was revealed in all published cases, although we observed only few intratumoral lymphocytes, in contrast to the other authors&#x2019; observations [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>].</p>
<p>Grading of cervical SCC is a sensitive subject since a wide variety of grading systems have been used, and none of them have been universally accepted and adopted in clinical practice [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. This is because none of them has been proven to be reproducible or prognostically meaningful [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. Interestingly, however, this does not prevent the general consensus that three classical grades are used: G1 (well differentiated), G2 (moderately differentiated) and G3 (poorly differentiated) [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. Some experts have recommended a modified historical Broder&#x2019;s system, which is based on the degree of keratinization, cytological atypia, and mitotic activity [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B19">19</xref>]. Most of our case consists of large cells with abundant cytoplasm, forming distinct keratin pearls. This would speak for G1. However, areas of high-grade cells with poor cytoplasm and crowded nuclei, resembling HSIL, were detected deep in the tumor. Moreover, areas of multinucleated pleomorphic cells containing large bizarre nuclei and high mitotic activity, including pathological mitoses, were detected. In view of the above, we classified the case arbitrarily as G2 (moderately differentiated).</p>
<p>Previous cases of OGC-rich squamous cell carcinoma of the uterine cervix were reported in middle- and old-aged patients, with only one case in a person younger than 40 years [<xref ref-type="bibr" rid="B8">8</xref>] (<xref ref-type="table" rid="T1">Table 1</xref>). To our knowledge, the present patient is the youngest person (33 yo.) with this type of tumor reported. What is interesting, both present and the other one below 40 yo. Came from Europe, making them two out of three cases reported in the Old Continent. However, given the small number of reported cases, this is most likely the work of chance.</p>
<p>All the previously reported cases of OGC-rich cervical SCC were symptomatic. Irregular vaginal bleeding was the most commonly reported clinical manifestation, followed by weight loss, whereas other symptoms were reported in single cases: abdominal bloating and coitorrhagia (bleeding after sexual intercourse) [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B18">18</xref>]. Therefore, the present case is the first case of clinically silent cervical SCC with OGCs. The early detection of invasive cancer in the present case was made possible only by routine cytological screening. These findings provide strong evidence of the effectiveness of screening for cervical cancer. Owing to the early stage of malignancy, the medical council decided that no further treatment was required after radical hysterectomy, making it the first case reported without adjuvant treatment. We may assume that the lack of clinical manifestations in the present case is consistent with the significantly smaller diameter of the lesion (10.5&#xa0;mm) than in previous cases. The diameters of the previous cases were within the range of 25&#x2013;60&#xa0;mm.</p>
<p>Owing to the small number of reported cases, it is impossible to draw conclusions about the potential prognostic or predictive value of OGC-rich morphology. The other factor that makes this impossible is the fact, rightly noted in the work of Castillo et al., that the reported cases had too short follow-up periods [<xref ref-type="bibr" rid="B8">8</xref>]. Moreover, the reported cases have other clinicopathological features that could potentially affect patient prognosis. The author of the first 2 cases reported dead of disease [<xref ref-type="bibr" rid="B15">15</xref>]. In contrast, the death rate of the following cases was less than 30% (2/7 patients) (<xref ref-type="table" rid="T1">Table 1</xref>). The two first reported cases with poor outcomes had sarcomatoid component, which was appropriately noted in the review by Castillo et al. [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. The interval between the first two and the remaining reported cases was 14&#xa0;years. In addition to morphology, the change in the death rate may reflect the global decrease in cervical cancer death, owing to tremendous progress in prevention and treatment. Progress in prevention is apparent in the fact that the first four cases were FIGO IB2, whereas the following four, including the present case, were FIGO IB1 (one case reported in the conference abstract lacks data [<xref ref-type="bibr" rid="B18">18</xref>]). Our case was classified as FIGO IB1 because the colposcopic appearance highly supported the clinical diagnosis of HSIL/suspicious for invasion (FIGO IA is limited to &#x201c;invasive carcinoma that can be diagnosed only by microscopy&#x201d; [<xref ref-type="bibr" rid="B22">22</xref>]). Furthermore, the fatal outcome in the subgroup of the later-reported nonsarcomatoid cases involved women 79 and 84 yo., whereas the other cases were younger than 50&#xa0;years. These findings support the view that age may be an additional causal factor of poor prognosis in this subgroup.</p>
<p>In view of the facts described in this paragraph, it is therefore understandable that OGC-rich squamous cell carcinoma of the uterine cervix has not yet been recognized as a special histologic subtype either by the WHO or any other group of experts. Further studies are needed to better understand the biological behavior and long-term prognosis of this rare subtype. We hope that this work will encourage pathologists who encounter this phenomenon during routine diagnostic practice to report their cases. Given the low prevalence of this morphologic pattern, each reported case is of considerable value.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s4">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="s5">
<title>Ethics statement</title>
<p>Ethical approval was not required for the study involving retrospective data in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and the institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec sec-type="author-contributions" id="s6">
<title>Author contributions</title>
<p>LF performed the histological examination, was a major contributor to the writing of the manuscript, interpreted the patient data, took the microscopic photographs and prepared the figures. BD operated on the patient, interpreted the patient data, described the surgical procedure, took photographs during colposcopy and revised the manuscript. WH interpreted the patient data and revised the manuscript. AH provided a second-look opinion on the histological examination, interpreted the patient data and revised the manuscript. All four authors approved the final text. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. The publication fee was covered by the Polish Ministry of Science and Higher Education as part of the statutory subsidy for Wroclaw Medical University (grant no. SUBZ. A430.25.079).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s9">
<title>Generative AI statement</title>
<p>The authors declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s10">
<title>Abbreviations</title>
<p>ACR, alive with complete regression; CT, chemotherapy; DOD, dead of disease; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; HR HPV, high-risk human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; IC NST, invasive carcinoma of no special type (breast); IHC, immunohistochemistry; LBC, liquid-based cytology; LEEP, loop electrosurgical excision procedure; LLETZ, large loop excision of the transformation zone; LSIL, low-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy; OGC, osteoclast-like giant cell; qPCR, quantitative polymerase chain reaction; RT, radiotherapy; SCC, squamous cell carcinoma; SP, surgical procedure; TV USG, transvaginal ultrasound; WHO, World Health Organization.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ervik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Laversanne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Colombet</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mery</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Global cancer observatory</article-title>: <source>Cancer Today</source>. (<year>2024</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://gco.iarc.who.int/today">https://gco.iarc.who.int/today</ext-link>. (Accessed September 16, 2024)</comment>.</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="book">
<collab>WHO Classification of Tumours</collab>. <source>Female genital tumours</source>. <edition>Vol 4. 5th ed</edition>. <publisher-name>Lyon: International Agency for Research on CancerIARC</publisher-name> (<year>2020</year>).</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Turashvili</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Pathology Outlines - HPV associated cervical squamous cell carcinoma</article-title>. (<year>2024</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.pathologyoutlines.com/topic/cervixscc.html">https://www.pathologyoutlines.com/topic/cervixscc.html</ext-link>. (Accessed September 29, 2024)</comment>.</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>David Chhieng</surname>
<given-names>PH</given-names>
</name>
</person-group>. <source>Cytology and surgical pathology of gynecologic neoplasms</source>. <publisher-name>New York: Humana Press</publisher-name> (<year>2011</year>). <pub-id pub-id-type="doi">10.1007/978-1-60761-164-6</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Dallenbach-Hellweg</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Knebel Doeberitz</surname>
<given-names>Mvon.</given-names>
</name>
<name>
<surname>Trunk</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <source>Color atlas of histopathology of the cervix uteri</source> (<year>2006</year>). p. <fpage>196</fpage>.</citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name>
<surname>Krishnamurti</surname>
<given-names>UG</given-names>
</name>
<name>
<surname>Crothers</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Birdsong</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Klepeis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Movahedi-Lankaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Otis</surname>
<given-names>CN</given-names>
</name>
</person-group>. <article-title>Protocol for the examination of resection specimens from patients with primary carcinoma of the uterine cervix</article-title> (<year>2023</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.cap.org/cancerprotocols">www.cap.org/cancerprotocols</ext-link> (Accessed September 30, 2024)</comment>.</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCluggage</surname>
<given-names>WG</given-names>
</name>
</person-group>. <article-title>Towards developing a meaningful grading system for cervical squamous cell carcinoma</article-title>. <source>J Pathol Clin Res</source> (<year>2018</year>) <volume>4</volume>(<issue>2</issue>):<fpage>81</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/CJP2.98</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castillo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perell&#xf3;-Fabregat</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Garc&#xed;a-G&#xf3;mez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Valdivieso</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jimeno</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Squamous cell carcinoma of uterine cervix with osteoclast-like giant cells: a case report</article-title>. <source>Mol Clin Oncol</source> (<year>2024</year>) <volume>21</volume>(<issue>2</issue>):<fpage>56</fpage>. <pub-id pub-id-type="doi">10.3892/MCO.2024.2754</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Elder</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Massi D</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Scolyer</surname>
<given-names>R</given-names>
</name>
</person-group>. <source>WHO classification of tumours. Skin tumours. 4th editio</source>. <publisher-name>Lyon: International Agency for Research on Cancer</publisher-name> (<year>2018</year>).</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="book">
<collab>WHO Classification of Tumours</collab>. <source>Digestive system tumours</source>. <edition>Vol 1. 5th ed</edition>. <publisher-name>Lyon: International Agency for Research on Cancer</publisher-name> (<year>2019</year>).</citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="book">
<collab>WHO Classification of Tumours</collab>. <source>Breast tumours. 5th editio</source>. <publisher-name>Lyon: International Agency for Research on Cancer</publisher-name> (<year>2003</year>).</citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cyrta</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Benoist</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Masliah-Planchon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Pierron</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fuhrmann</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression</article-title>. <source>Mod Pathol</source> (<year>2022</year>) <volume>35</volume>(<issue>11</issue>):<fpage>1624</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/S41379-022-01112-9</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sasajima</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sugita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morikawa</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Uterine cervical squamous cell carcinoma with reactive multinucleated giant cells expressing cluster of differentiation 204: a case report and literature review</article-title>. <source>J Obstet Gynaecol Res</source> (<year>2020</year>) <volume>46</volume>(<issue>10</issue>):<fpage>2174</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/JOG.14404</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Khurana</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Osteoclastic giant cell rich carcinoma cervix: a rare entity</article-title>. <source>J Obstet Gynaecol (Lahore)</source> (<year>2012</year>) <volume>32</volume>(<issue>5</issue>):<fpage>499</fpage>&#x2013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.3109/01443615.2012.677873</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pang</surname>
<given-names>LC</given-names>
</name>
</person-group>. <article-title>Sarcomatoid squamous cell carcinoma of the uterine cervix with osteoclast-like giant cells: report of two cases</article-title>. <source>Int J Gynecol Pathol</source> (<year>1998</year>) <volume>17</volume>(<issue>2</issue>):<fpage>174</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/00004347-199804000-00014</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alem&#xe1;n-Meza</surname>
<given-names>L</given-names>
</name>
<name>
<surname>G&#xf3;mez-Mac&#xed;as</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Barboza-Quintana</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Garza-Guajardo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Loya-Solis</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Osteoclastic giant cell rich squamous cell carcinoma of the uterine cervix: a case report and review of the literature</article-title>. <source>Case Rep Pathol</source> (<year>2014</year>) <volume>2014</volume>:<fpage>1</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1155/2014/415328</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Squamous cell carcinoma of the uterine cervix associated with osteoclast-like giant cells: a case report and review of the literature</article-title>. <source>Oncol Lett</source> (<year>2014</year>) <volume>8</volume>(<issue>4</issue>):<fpage>1595</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2014.2384</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tziakou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Arkoumani</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ieronymaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galanopoulos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zizi-Sermpetzoglou</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Squamous cell carcinoma of the uterine cervix associated with osteoclast-like giant cells: a case report</article-title>. <source>VIRCHOWS Arch</source> (<year>2020</year>) <volume>477</volume>:<fpage>S303</fpage>&#x2013;<lpage>S303</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2014.2384</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Blaustein</surname>
<given-names>A</given-names>
</name>
</person-group>. <source>Blaustein&#x2019;s pathology of the female genital tract</source>. <publisher-name>Springer International Publishing</publisher-name> (<year>2019</year>).</citation>
</ref>
<ref id="B20">
<label>20.</label>
<citation citation-type="book">
<source>Cervical cancer</source> (<year>2024</year>). <comment>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/cervical-cancer">https://www.who.int/news-room/fact-sheets/detail/cervical-cancer</ext-link>. (Accessed December 7, 2024)</comment>.</citation>
</ref>
<ref id="B21">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bogani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sopracordevole</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ciavattini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ghelardi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vizza</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vercellini</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: a focus on the potential role of vaccination</article-title>. <source>Tumori</source> (<year>2024</year>) <volume>110</volume>(<issue>2</issue>):<fpage>139</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1177/03008916231208344</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatla</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Sankaranarayanan</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Cancer of the cervix uteri: 2021 update</article-title>. <source>Int J Gynaecol Obstet</source> (<year>2021</year>) <volume>155</volume>(<issue>Suppl. 1</issue>):<fpage>28</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/IJGO.13865</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>